Table 1. Demographic and disease characteristics of the study population.
SD: Standard deviation; IQR: Interquartile range; n/a: not applicable; NS: not significant.
| CD n = 737 | UC n = 566 | P-value | |
|---|---|---|---|
| Male gender (%) | 295 (4.0) | 300 (53.0) | <0.01 |
| Age—years (± SD) | 50.5 (13.5) | 52.4 (12.9) | 0.01 |
| Smoking (%) | <0.01 | ||
| Current | 137 (18.6) | 45 (8.0) | |
| Never | 382 (51.8) | 336 (59.4) | |
| Ex-smoker | 218 (29.6) | 185 (32.7) | |
| Low education (%) | 445 (60.4) | 314 (55.5) | 0.08 |
| Disease duration—median (IQR) | 18.2 (10.1–18.2) | 16.0 (9.0–16.0) | <0.01 |
| Disease localisation (%) | |||
| Large bowel | 204 (27.7) | 566 (100) | n/a |
| Small bowel | 152 (20.6) | ||
| Both small and large bowel | 361 (49.0) | ||
| Unknown | 20 (2.7) | ||
| Penetrating disease course (%) | 400 (54.3) | n/a | |
| Clinical remission (%) | 618 (83.9) | 452 (79.9) | 0.06 |
| Abdominal surgery (%) | 416 (56.4) | 106 (18.7) | <0.01 |
| Medication use (%) | |||
| Mesalazine | 175 (23.7) | 373 (65.9) | <0.01 |
| Azathioprine | 189 (25.6) | 91 (16.1) | <0.01 |
| Mercaptopurine | 51 (6.9) | 36 (6.4) | NS |
| Methotrexate | 25 (3.4) | 1 (0.2) | NS |
| Prednisone | 37 (4.9) | 31 (5.5) | NS |
| Budesonide | 44 (6.0) | 19 (3.4) | NS |
| Infliximab | 72 (9.8) | 14 (2.5) | <0.01 |
| Adalimumab | 85 (11.5) | 5 (0.9) | <0.01 |